DFOB-LDX | 1149568-62-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: DFOB-LDX
• 英文别名: N-[5-[acetyl(hydroxy)amino]pentyl]-N'-[5-[[4-[5-[[4-[3,5-bis(2-hydroxyphenyl)-1,2,4-triazol-1-yl]benzoyl]amino]pentyl-hydroxyamino]-4-oxobutanoyl]amino]pentyl]-N'-hydroxybutanediamide
• CAS: 1149568-62-6
• 化学式: C₄₆H₆₁N₉O₁₁
• 分子量: 916.044
• InChiKey: ANJVCUINWYSXTQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  66
• 可旋转键数：
  28
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.43
• 拓扑面积：
  280
• 氢给体数：
  8
• 氢受体数：
  13

反应信息

• 作为产物：
  描述：

  甲磺酸去铁敏 、 地拉罗司 在 1-羟基苯并三唑 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 、 N,N-二异丙基乙胺 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 以65%的产率得到DFOB-LDX
  参考文献：
  名称：

  Conjugates of Desferrioxamine B (DFOB) with Derivatives of Adamantane or with Orally Available Chelators as Potential Agents for Treating Iron Overload

  摘要：

  Desferrioxamine B (DFOB) conjugates with adamantane-1-carboxylic acid, 3-hydroxyadamantane-1-carboxylic acid, 3,5-dimethyladamantane-1-carboxylic acid, adamantane-1-acetic acid, 4-methylphenoxyacetic acid, 3-hydroxy-2-methyl-4-oxo-1-pyridineacetic acid (N-acetic acid derivative of deferiprone), or 4-[3,5-bis(2-hydroxyphenyl)-1,2,4-triazol- 1-yl]benzoic acid (deferasirox) were prepared and the integrity of Fe(III) binding of the compounds was established from electrospray ionization mass spectrometry and RP-HPLC measurements. The extent of intracellular Fe-59 mobilized by the DFOB-3,5-dimethyladamantane-1-carboxylic acid adduct was 3-fold greater than DFOB alone, and the IC50 value of this adduct was 6- or 15-fold greater than DFOB in two different cell types. The relationship between logP and Fe-59 mobilization for the DFOB conjugates showed that maximal mobilization of intracellular Fe-59 Occurred at a logP value similar to 2.3. This parameter, rather than the affinity for Fe(III), appears to influence the extent of intracellular Fe-59 mobilization. The low toxicity-high Fe mobilization efficacy of selected adamantane-based DFOB conjugates underscores the potential of these compounds to treat iron overload disease in patients with transfusional-dependent disorders such as beta-thalassemia.

  DOI：

  10.1021/jm9016703

文献信息

• DESFERRIOXAMINE CONJUGATES, DERIVATIVES AND ANALOGUES
  申请人：Codd Rachel

  公开号：US20100273847A1

  公开（公告）日：2010-10-28

  The present invention relates to desferoxamine conjugates, derivatives and analogues thereof. In particular, the present invention relates to desferoxamine conjugates, analogues and derivatives thereof, and methods for reducing levels of metals, especially iron, in a mammal. Uses of the compounds according to the invention are also provided. Compounds of the present invention may also be used to treat iron dyshomeostasis disorders, cancer, malaria and fungal infections. The compounds of the invention may be formulated into a pharmaceutical composition or packaged into kits.

  本发明涉及去铁胺共轭物、衍生物和类似物。特别是，本发明涉及去铁胺共轭物、类似物和衍生物，以及在哺乳动物中降低金属水平，特别是铁的方法。本发明还提供了根据本发明的化合物的用途。本发明的化合物也可用于治疗铁代谢失调疾病、癌症、疟疾和真菌感染。本发明的化合物可制成药物组合物或装入试剂盒中。
• US8309583B2
  申请人：——

  公开号：US8309583B2

  公开（公告）日：2012-11-13
• Conjugates of Desferrioxamine B (DFOB) with Derivatives of Adamantane or with Orally Available Chelators as Potential Agents for Treating Iron Overload
  作者：Joe Liu、Daniel Obando、Liam G. Schipanski、Ludwig K. Groebler、Paul K. Witting、Danuta S. Kalinowski、Des R. Richardson、Rachel Codd

  DOI：10.1021/jm9016703

  日期：2010.2.11

  Desferrioxamine B (DFOB) conjugates with adamantane-1-carboxylic acid, 3-hydroxyadamantane-1-carboxylic acid, 3,5-dimethyladamantane-1-carboxylic acid, adamantane-1-acetic acid, 4-methylphenoxyacetic acid, 3-hydroxy-2-methyl-4-oxo-1-pyridineacetic acid (N-acetic acid derivative of deferiprone), or 4-[3,5-bis(2-hydroxyphenyl)-1,2,4-triazol- 1-yl]benzoic acid (deferasirox) were prepared and the integrity of Fe(III) binding of the compounds was established from electrospray ionization mass spectrometry and RP-HPLC measurements. The extent of intracellular Fe-59 mobilized by the DFOB-3,5-dimethyladamantane-1-carboxylic acid adduct was 3-fold greater than DFOB alone, and the IC50 value of this adduct was 6- or 15-fold greater than DFOB in two different cell types. The relationship between logP and Fe-59 mobilization for the DFOB conjugates showed that maximal mobilization of intracellular Fe-59 Occurred at a logP value similar to 2.3. This parameter, rather than the affinity for Fe(III), appears to influence the extent of intracellular Fe-59 mobilization. The low toxicity-high Fe mobilization efficacy of selected adamantane-based DFOB conjugates underscores the potential of these compounds to treat iron overload disease in patients with transfusional-dependent disorders such as beta-thalassemia.